Publications by authors named "Becky Hooper"

Claim this Profile
N
Network Meta-analysis of 1.5% Ruxolitinib Cream Versus Systemic Agents in the Treatment of Moderate Atopic Dermatitis.
Melinda J Gooderham, H Chih-Ho Hong, Di Wang, Becky Hooper, Avery Hughes-Martin

Dermatol Ther (Heidelb)· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative efficacy and safety of tislelizumab and other programmed cell death protein 1 inhibitors in first-line treatment of advanced gastroesophageal cancers: a systematic review and network meta-analysis.
Jaffer A Ajani, Maria Alsina, Markus Moehler, Keun-Wook Lee, Wenxi Tang, Becky Hooper

Gastric Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Time to Onset of Action for Biologics and Targeted Treatments in Psoriasis: Systematic Targeted Literature Review and Network Meta-Analysis.
Kim A Papp, Ron Vender, Kerri Purdy, Fiona Lovegrove, Irina Oroz, Becky Hooper

Dermatol Ther (Heidelb)· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
One-Year Efficacy of Guselkumab Versus Advanced Therapies for the Treatment of Moderately to Severely Active Crohn's Disease: A Network Meta-Analysis.
Tim Disher, Dominik Naessens, Myrlene Sanon, Ashley Bonner, Jenna Ellis, Becky Hooper

Adv Ther· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Matching-Adjusted Indirect Comparison of Recombinant Factor IX Albumin Fusion Protein Versus Recombinant Factor IX Fc Fusion Protein for Weekly Prophylactic Treatment of Hemophilia B.
Benoit Guillet, Songkai Yan, Becky Hooper, Douglass Drelich, Jason Steenkamp

Adv Ther· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Meta-analysis of ciltacabtagene autoleucel versus physician's choice therapy for the treatment of patients with relapsed or refractory multiple myeloma.
Luciano J Costa, Parameswaran Hari, Jesus G Berdeja, Valerio De Stefano, Francesca Gay, Becky Hooper

Curr Med Res Opin· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CDK4/6 inhibitors in HR+/HER2- advanced/metastatic breast cancer: a systematic literature review of real-world evidence studies.
Nadia Harbeck, Meaghan Bartlett, Dean Spurden, Becky Hooper, Lin Zhan

Future Oncol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Matching-adjusted indirect comparison of palbociclib versus ribociclib and abemaciclib in hormone receptor-positive/HER2-negative advanced breast cancer.
Hope S Rugo, Anja Haltner, Lin Zhan, Anh Tran, Eustratios Bananis, Becky Hooper

J Comp Eff Res· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis